Tevogen Bio Holdings Inc. announced plans to expand the target population for its treatment TVGN 489 to include patients aged 65 and older, enhancing its market potential in specialty pharmaceuticals.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback